FXIII polymorphisms, fibrin clot structure and thrombotic risk.
Fibrin clot structure is highly dependent on factor XIII activity. Activated FXIII catalyzes the formation of the peptide bonds between the gamma and alpha chains in noncovalently bound fibrin polymers and incorporates various adhesive and antifibrinolytic proteins into the final fibrin clot. In the absence of activated FXIII, clots are unstable and susceptible to fibrinolysis. Several studies have examined the effects of FXIII polymorphisms on final fibrin clot structure and clinical thrombotic risk. The Val34Leu FXIII polymorphism is associated with increased activation by thrombin. In the presence of saturating thrombin concentrations, however, FXIIIa specific enzyme activity is not affected by genetic polymorphisms. Fibrin clots formed in the presence of the FXIII 34Leu polymorphisms do tend to be thinner and less porous, however. The effects of prothrombin concentrations on clot structure have suggested that thinner clots are more resistant to fibrinolysis and associated with increased thrombotic risk. Most clinical studies of 34Leu FXIII carriers, however, have demonstrated a lower incidence of both venous and arterial thrombosis in carriers of the mutant allele compared to Val/Val carriers. One recent study has suggested that the interactions between FXIII phenotype and plasma fibrinogen concentrations significantly influence clinical thrombotic risk.
Kobbervig
Catie
C
Department of Medicine, University of Wisconsin, 600 Highland Avenue, Room H4534, 53792 Madison, USA. williams@medicine.wisc.edu
Williams
Eliot
E
D000818:Animals; D001777:Blood Coagulation / Q000235:genetics; D005176:Factor XIII / Q000235:genetics* / Q000502:physiology; D005337:Fibrin / Q000737:chemistry / Q000502:physiology / Q000648:ultrastructure*; D006801:Humans; D011110:Polymorphism, Genetic; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology / Q000235:genetics*
D005337:Fibrin; D005176:Factor XIII